Topic: ESOPRS 2021 ePoster sessions
Time: Sep 17, 2021 16:00 Amsterdam, Berlin, Rome, Stockholm, Vienna, 15:00 London
(plain text version here)
Medical Cannabis Oil for Benign Essential Blepharospasm: A Prospective, Randomized Controlled Pilot Study
Author: Ofira Zloto
ePoster Number: 104
To examine the efficacy and safety of medical cannabis in benign-essential-blepharospasm (BEB).
This is a prospective, double-blind, placebo-controlled study. All consecutive adult BEB patients who had been successfully treated with BTX-A injections between 3/2019 and 2/2020 were recruited. The study patients were randomly allocated into a treatment and a control (placebo) group in a 1:1 ratio. The treatment group used cannabis drops and the control group used cannabis oil drops during the first 6 weeks of the study, and both groups were treated with the medical cannabis drops during the second 6 weeks. The cannabis dose was gradually increased for each patient depending upon effect and tolerability.
Three patients were included in each group. The mean duration of spasm attack during the first 6 weeks was 4.29 minutes in the treatment group and 73.9 minutes in the placebo group (P < 0.01). During the last 6 weeks, the treatment group used an average of 6.27 drops and the placebo group used an average of 5.36 drops (P = 0.478). There were 61 spasm events in the treatment group and 94 spasm events in the placebo group(P = 0.05). The mean duration of spasm attack was 1.77 and 8.96 minutes, respectively (P < 0.01). The side effects were mild, and they included general fatigue, dry mouth, and insomnia.
Medical-cannabis can be an effective and safe treatment for BEB as a second line after BTX-A injections when used for 3 months. No significant ocular or systemic side-effects were associated with the treatment
|First name||Last name||Base Hospital / Institution|
Abstract ID: 21-181